CompoAtlas

雅 綺麗御守錠

雅 綺麗御守錠 : Product registered in Taiwan. This registration does not constitute authorisation for sale in France or the European Union. It does not demonstrate the safety or efficacy of the product.

TFDA, Taiwan tablets, capsules and medical nutrition registers, retrieved 27 October 2026.

Taiwan Food and Drug Administration (TFDA), Open Government Data License, version 1.0

Open Government Data License, version 1.0

The foreign register category does not determine the regulatory category of the product in France.

French and European references for recognised ingredients

No point flagged by the rules applied to recognised ingredients.

Unidentified ingredients are not assessed. The absence of a signal does not establish product compliance.

Published composition

Published ingredientPublished text and quantityIdentified nutrient or substance
MORINGAMORINGANot identified
DEXTRINDEXTRINNot identified
ROYAL JELLYROYAL JELLYGelée royale
VITAMIN B1 (THIAMINE MONONITRATE)VITAMIN B1 (THIAMINE MONONITRATE)Vitamine B1 (thiamine)
VITAMIN B6 (PYRIDOXINE HYDROCHLORIDE)VITAMIN B6 (PYRIDOXINE HYDROCHLORIDE)Vitamine B6
VITAMIN B12VITAMIN B12Vitamine B12
MALTODEXTRINMALTODEXTRINMaltodextrine
SODIUM CITRATESODIUM CITRATENot identified
CITRIC ACIDCITRIC ACIDAcide citrique
CYANOCOBALAMINCYANOCOBALAMINVitamine B12
YUZU POWDERYUZU POWDERNot identified
YUZU FLAVORYUZU FLAVORNot identified
STARCH SODIUM OCTENYL SUCCINATESTARCH SODIUM OCTENYL SUCCINATENot identified
VITAMIN E (D-ALPHA TOCOPHEROL)VITAMIN E (D-ALPHA TOCOPHEROL)Vitamine E
SAFFLOWER YELLOWSAFFLOWER YELLOWNot identified
MICROCRYSTALLINE α-CELLULOSEMICROCRYSTALLINE α-CELLULOSENot identified
ASPARTAMEASPARTAMENot identified
TARTARIC ACIDTARTARIC ACIDNot identified
PALATINOSEPALATINOSENot identified
SODIUM BICARBONATESODIUM BICARBONATEBicarbonate de sodium
SODIUM METAPHOSPHATESODIUM METAPHOSPHATENot identified
SUGARSUGARNot identified
α-CYCLODEXTRINα-CYCLODEXTRINNot identified
CALCIUM STEARATECALCIUM STEARATENot identified
SILICON DIOXIDESILICON DIOXIDENot identified

The imported data provide no usable daily dosage. No daily dose is estimated and no comparison with dose limits is performed. A published quantity may refer to a preparation or an unspecified unit. Chinese names are retained without translation.

Product record

Registration number
1139019387
Chinese name
雅 綺麗御守錠
English name
SPARKLING MORINGA SEED ENERGY TABLET
Type
Imported tablets and capsules
Published status
Status not provided in this export; the validity date is shown separately
Licence holder
立雅生物科技有限公司
Registration date
2024-05-15
Published validity end
2029-05-15

Original register data

View published fields and their variants
Product name
雅 綺麗御守錠
Active ingredients
MORINGA;;DEXTRIN;;MORINGA;;ROYAL JELLY;;VITAMIN B1 (THIAMINE MONONITRATE);;VITAMIN B6 (PYRIDOXINE HYDROCHLORIDE);;VITAMIN B12;;MALTODEXTRIN;;SODIUM CITRATE;;CITRIC ACID;;CYANOCOBALAMIN;;YUZU POWDER;;YUZU POWDER;;DEXTRIN;;YUZU FLAVOR;;DEXTRIN;;YUZU POWDER;;STARCH SODIUM OCTENYL SUCCINATE;;VITAMIN E (D-ALPHA TOCOPHEROL);;SAFFLOWER YELLOW;;SAFFLOWER YELLOW;;MICROCRYSTALLINE α-CELLULOSE;;ASPARTAME;;TARTARIC ACID;;PALATINOSE;;SODIUM BICARBONATE;;SODIUM METAPHOSPHATE;;SUGAR;;MICROCRYSTALLINE α-CELLULOSE;;DEXTRIN;;α-CYCLODEXTRIN;;CALCIUM STEARATE;;SILICON DIOXIDE;;
Valid until
1180515
Registration number
1139019387
Licence holder
立雅生物科技有限公司
Registration date
1130515
Published reference
DHC0B390193878
Published English name
SPARKLING MORINGA SEED ENERGY TABLET

Official source

View the official register, number 1139019387

Taiwan Food and Drug Administration (TFDA), Open Government Data License, version 1.0

Open Government Data License, version 1.0

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • ROYAL JELLY
    Read the warning, when it applies and the studies cited

    ROYAL JELLY

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Contraindications

    Do not use if you have a history of asthma or allergies (TGA 2001; Leung et al. 1997; Harwood et al. 1996; Laporte et al. 1996; Thien et al. 1996; Leung et al. 1995; Peacock et al. 1995; Bullock 1994).

    Sources cited by Health Canada (8)
    • Bullock RJ. Fatal royal-jelly induced asthma. Medical Journal of Australia 1994;160:44. PubMed Case report
    • Harwood M, Harding S, Beasley R, Frankish PD. Asthma following royal jelly. The New Zealand Medical Journal 1996;109:325. PubMed Case report
    • Laporte JR, Ibaanez L, Vendrell L, Ballarin E. Bronchospasm induced by royal jelly. Allergy 1996;51:440. PubMed
    • Leung R, Ho A, Chan J, Choy D, Lai CK. Royal jelly consumption and hypersensitivity in the community. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 1997;27(3):333-336. PubMed
    • Leung R, Thien FC, Baldo B. Royal Jelly-induced asthma and anaphylaxis: clinical characteristics and immunologic correlations. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 1995;96:1004-1007. PubMed Case report
    • Peacock S, Muray V, Turton C. Respiratory distress and royal jelly. British Medical Journal 1995;311:1472. PubMed Case report
    • TGA 2001: Australian Therapeutic Goods Administration. CMEC 28: Complementary Medicines Evaluation Committee, Extracted Ratified Minutes twenty-eight Meeting, 27-28 July 2001. Australian Government Department of Health and Aging, Sydney, Australia; 2001. [Accessed 2025 February 5]. Available from: https://www.tga.gov.au/sites/default/files/cmec-minutes-28.pdf
    • Thien FC, Leung R, Baldo BA, Weiner JA, Plomley R, Czarny D. Asthma and anaphylaxis induced by royal jelly. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 1996;26(2):216-222. PubMed

    Known adverse reactions

    Stop use if hypersensitivity/allergy occurs (Leung et al. 1997; Laporte et al. 1996; Thien et al. 1996; Leung et al. 1995; Peacock et al. 1995).

    Sources cited by Health Canada (6)
    • Laporte JR, Ibaanez L, Vendrell L, Ballarin E. Bronchospasm induced by royal jelly. Allergy 1996;51:440. PubMed
    • Leung R, Ho A, Chan J, Choy D, Lai CK. Royal jelly consumption and hypersensitivity in the community. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 1997;27(3):333-336. PubMed
    • Leung R, Thien FC, Baldo B. Royal Jelly-induced asthma and anaphylaxis: clinical characteristics and immunologic correlations. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 1995;96:1004-1007. PubMed Case report
    • Peacock S, Muray V, Turton C. Respiratory distress and royal jelly. British Medical Journal 1995;311:1472. PubMed Case report
    • Thien FC, Leung R, Baldo BA, Weiner JA, Plomley R, Czarny D. Asthma and anaphylaxis induced by royal jelly. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 1996;26(2):216-222. PubMed
    • Harwood M, Harding S, Beasley R, Frankish PD. Asthma following royal jelly. The New Zealand Medical Journal 1996;109:325. PubMed Case report

    Health Canada monograph dated 24 April 2026

They concern the ingredient, not this product or its dose. They do not replace medical advice.

The evidence date of this ingredient list is unknown.

Has the product changed? Photograph the packaging.

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “雅 綺麗御守錠”, https://compoatlas.com/en/supplements/taiwan/1139019387-sparkling-moringa-seed-energy-tablet, updated 27 October 2026.

Enter to analyse, Shift+Enter for a new line